Typhoid Fever: Combined vs. Single Antibiotic Therapy

checkorphan
Learn more about:
Typhoid fever
Related Clinical Trial
Transcriptomic Responses for the Identification of Pathogens Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants Commercial Typhoid Tests Validation Trial Commercial Typhoid Tests Validation WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial) Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old) Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old) Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort Safety and Immunogenicity of Typhax, a Typhoid Vaccine Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III) Investigating Enteric Fever – Salmonella Typhi and Paratyphi Challenge Study Induction of Gut Permeability by an Oral Vaccine Studies of Immune Responses to Orally Administered Vaccines in Developing Country Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants Typhoid Fever: Combined vs. Single Antibiotic Therapy Vaccines Against Salmonella Typhi Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults CVD 909 Vi Prime Boost Study Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso Understanding Typhoid Disease After Vaccination Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood Global Genomic and Proteomic Profiling of African Children With Typhoid Fever

Brief Title

Typhoid Fever: Combined vs. Single Antibiotic Therapy

Official Title

Typhoid Fever: Combined vs. Single Antibiotic Therapy. A Prospective Randomized Controlled Study in Nepal.

Brief Summary

      The current study goal is to examine the effect of Cephalosporins, Azithromycin and the
      combination of both on typhoid fever therapy in endemic population.

      The investigator's hypothesize that the combination of azithromycin and ceftriaxone may prove
      superior to each drug, ceftriaxone or azithromycin, alone.

Detailed Description

      Typhoid Fever is a highly prevalent infection in the Indian subcontinent. Due to multidrug
      resistant strains in these areas, third generation cephalosporins, such as ceftriaxone, are
      the treatment of choice. However, the latter regimen exhibits a slow response with mean time
      of 5 to 7 days or even longer to defervescence, which could be attributed to poor penetration
      capability of the drug into cells, and thus difficulty to eradicate the bacteria from the
      intracellular niche.

      Attempts have been made to overcome this setback by introducing alternative antibiotic
      regimens, such as azithromycin. However studies comparing between azithromycin and a
      third-generation cephalosporin for the treatment of typhoid fever in adult population in the
      Indian subcontinent are lacking.

      Over the last few years our approach towards non-immunized travelers, who acquired typhoid
      fever in the Indian subcontinent, was to administer a combination therapy of intravenous
      ceftriaxone with oral azithromycin. The rationale of this dual regimen was its
      pharmacokinetic profile, which suggests a complimentary action of the two agents -
      ceftriaxone on the extracellular compartment and azithromycin on the intracellular
      compartment. Moreover, in our clinical experience, preliminary published data has proven
      combination therapy significantly superior to ceftriaxone alone albeit in a small group of
      travelers.

      In the current study the investigators intend to compare the efficacy of ceftriaxone vs.
      azithromycin and vs. combined therapy of both agents for the treatment of uncomplicated
      typhoid fever in terms of time to defervescence.

      4 different treatment strategies will be examined (as mentioned in the arm section). All
      participants will be checked for vital signs, will undergo physical examination, ECG,
      laboratory testing, blood, urine and stool culture and tests for susceptibility to
      antibiotics.

Study Phase

Phase 4

Study Type

Interventional

Primary Outcome

Fever clearance time

Secondary Outcome

 Treatment failure

Condition

Typhoid Fever

Intervention

ceftriaxone

Study Arms / Comparison Groups

 Ceftriaxone I.V
Description:  The participants in this arm will receive the following drug and dosage: adult: Ceftriaxone intravenous 2 gr once a day. Pediatric: intravenous 75 mg/kg ceftriaxone once a day (maximum dose 2.5 g/day). Patients will receive antibiotic treatment until defervescence and for 3 days afterwards. Patients will be hospitalized during the entire treatment course (including the afebrile period).

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

120

Start Date

August 2013

Completion Date

August 2015

Primary Completion Date

December 2014

Eligibility Criteria

        Inclusion Criteria:

          -  Blood culture-proven typhoid fever (S. typhi or S. paratyphi)

          -  Signed informed consent to participate in the study.

        Exclusion Criteria:

          -  Allergy to ceftriaxone or macrolides

          -  Major typhoid fever-associated complications

          -  Inability to swallow oral medication

          -  Underlying illness

          -  Pregnancy

          -  Lactation

          -  Treatment within the past 4 days with an antibiotic that may be effective against
             typhoid fever

Gender

All

Ages

2 Years - 80 Years

Accepts Healthy Volunteers

No

Contacts

Eli Schwartz, MD, DTMH, +97235308456, [email protected]

Location Countries

Nepal

Location Countries

Nepal

Administrative Informations

NCT ID

NCT02224040

Organization ID

64/12

Responsible Party

Principal Investigator

Study Sponsor

Sheba Medical Center

Study Sponsor

Eli Schwartz, MD, DTMH, Principal Investigator, Sheba Medical Center

Verification Date

August 2014